Dr. John Halpern submitted a lengthy response to the questions that we were asked to address by the IRB reviewing the MDMA/cancer anxiety study. Now we wait until the IRB meeting at the end of August to see if there are more questions. We’re feeling hopeful about an eventual resolution of all the issues.
